MAM
BXRX

Meeder Asset Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Meeder Asset Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Hold
0
– -$2K – 2643
2020
Q1 		– Sell
-3
Closed -$28.3K – 2142
2019
Q4 		$32K Buy
+3
New +$25.6K ﹤0.01% 1194

Other funds holding BXRX

NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Meeder Asset Management's BXRX Position: Q2 2020 in Review

Meeder Asset Management held its Baudax Bio, Inc. Common Stock (BXRX) position steady in Q2 2020 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2643.

Meeder Asset Management first reported a position in BXRX in Q4 2019 and has held it in 1 quarter since. The position peaked at $32K in Q4 2019. 38 funds tracked by Wall St. Rank hold BXRX as of Q2 2020.

  • Meeder Asset Management held 0 shares of Baudax Bio, Inc. Common Stock worth $0 as of Q2 2020.
  • Meeder Asset Management left its Baudax Bio, Inc. Common Stock share count unchanged in Q2 2020.
  • Baudax Bio, Inc. Common Stock made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2020, its #2643 holding.
  • Meeder Asset Management first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and has held it in 1 quarter since.
  • Meeder Asset Management's Baudax Bio, Inc. Common Stock position peaked at $32K in Q4 2019.
  • 38 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.